JP2023530245A5 - - Google Patents

Info

Publication number
JP2023530245A5
JP2023530245A5 JP2022575767A JP2022575767A JP2023530245A5 JP 2023530245 A5 JP2023530245 A5 JP 2023530245A5 JP 2022575767 A JP2022575767 A JP 2022575767A JP 2022575767 A JP2022575767 A JP 2022575767A JP 2023530245 A5 JP2023530245 A5 JP 2023530245A5
Authority
JP
Japan
Prior art keywords
tcr
polypeptide
seq
amino acid
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022575767A
Other languages
English (en)
Japanese (ja)
Other versions
JP7827645B2 (ja
JP2023530245A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036443 external-priority patent/WO2021252517A1/en
Publication of JP2023530245A publication Critical patent/JP2023530245A/ja
Publication of JP2023530245A5 publication Critical patent/JP2023530245A5/ja
Application granted granted Critical
Publication of JP7827645B2 publication Critical patent/JP7827645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022575767A 2020-06-09 2021-06-08 操作されたt細胞受容体および使用の方法 Active JP7827645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036539P 2020-06-09 2020-06-09
US63/036,539 2020-06-09
PCT/US2021/036443 WO2021252517A1 (en) 2020-06-09 2021-06-08 Engineered t cell receptors and methods of use

Publications (3)

Publication Number Publication Date
JP2023530245A JP2023530245A (ja) 2023-07-14
JP2023530245A5 true JP2023530245A5 (cg-RX-API-DMAC7.html) 2024-06-07
JP7827645B2 JP7827645B2 (ja) 2026-03-10

Family

ID=78845879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575767A Active JP7827645B2 (ja) 2020-06-09 2021-06-08 操作されたt細胞受容体および使用の方法

Country Status (6)

Country Link
US (1) US20230227526A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161555A4 (cg-RX-API-DMAC7.html)
JP (1) JP7827645B2 (cg-RX-API-DMAC7.html)
CN (1) CN116096740A (cg-RX-API-DMAC7.html)
CA (1) CA3186594A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021252517A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050010030A1 (en) * 2003-07-02 2005-01-13 Zang Jingwu Z. T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
PT3149031T (pt) * 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
EP3452514A1 (en) * 2016-05-06 2019-03-13 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
US11603519B2 (en) * 2017-02-06 2023-03-14 National Cancer Center Japan T-cell receptor
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
WO2019086665A1 (en) * 2017-11-06 2019-05-09 Immatics Biotechnologies Gmbh Novel engineered t cell receptors and immune therapy using the same
CN112566698A (zh) * 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞

Similar Documents

Publication Publication Date Title
JP2023528255A5 (cg-RX-API-DMAC7.html)
AU2014225788B2 (en) Engager cells for immunotherapy
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
CN118580363A (zh) 制导和导航控制蛋白及其制备和使用方法
JP2023548556A5 (cg-RX-API-DMAC7.html)
CN113286879A (zh) 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子
JP2020503883A5 (cg-RX-API-DMAC7.html)
EP4051402B1 (en) Cell selection and/or stimulation devices and methods of use
US20250283037A1 (en) Methods for stimulating and transducing t cells
CN111556756A (zh) 重组免疫细胞、制备方法和使用方法
KR20240032732A (ko) 암 면역요법을 위한 투약 요법
IL301995A (en) Cells comprising t cell-antigen couplers and uses thereof
CN113321727B (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
US20120027674A1 (en) Il-18 receptor as a novel target of regulatory t cells in cancer
CN117106059A (zh) 一种识别mage的t细胞受体及其应用
WO2022195241A1 (en) Cd160 binding domain
CN119613563A (zh) 编码car的核酸分子和含其的载体、car、含car的免疫细胞及其制造方法和含该细胞的医药组合物及提升细胞损伤活性的方法
CN111434691A (zh) Pd-l2单克隆抗体及其应用
CN109400697B (zh) 一种识别prame抗原短肽的tcr及其相关组合物
CN117659162A (zh) 一种识别apf的t细胞受体及其编码序列和应用
JP2024539273A5 (cg-RX-API-DMAC7.html)
EP3744737A1 (en) Human antibody and fragments thereof for use in the treatment of gastric cancer (gc) and other types of tumours expressing the mica protein (mhc class i chain-related protein a gene)
JP2024526836A5 (cg-RX-API-DMAC7.html)
CN119998452A (zh) 编码car的核酸分子和包含其的载体、car、包含car的免疫细胞和包含该细胞的药物组合物及包含car的免疫细胞的制备方法
CN117915931A (zh) 癌症免疫疗法的给药方案